Biohealth Innovation
HIMSS is working with the U.S. Department of Health and Human Services, through HHS' Innovator in Residence program, to develop a strategy for nationwide patient data matching.
HIMSS is currently recruiting an innovator in residence to work toward an implementation plan for the near-term deployment of consistent patient data matching, building on the work of the Office of the National Coordinator for Health IT and other healthcare partners.
Former Microsoft executive Kurt DelBene will take over day-to-day responsibility for the smooth running of HealthCare.gov. The government’s insurance marketplace is just recovering from the pain of a bungled launch. Jeff Zients, who is credited for bringing it back on track, is about to start his new job as a director of the National Economic Council.
DelBene has agreed to stay at HealthCare.gov for at least through the first six months of the year. His stint begins Dec. 18.
On Friday, the Food and Drug Administration approved a pill called Orenitram, to treat pulmonary arterial hypertension. It is an oral version of an injected drug called Remodulin, which treats the same disease. According to Mark Schoenebaum at ISI Group, the approval is “an enormous surprise — arguably, one of the top 10 biggest upside surprises in the history of the biotech sector.”
Why? Well, for one thing, Orenitram’s benefit isn’t that compelling. The FDA-approved labeling for the product characterizes the treatment effect as “small.” And the FDA had already rejected it twice, in March and October 2012. It seemed nearly impossible that the medicine would be approved without additional data. Yet that’s exactly what has happened.
We have the sharks for an all healthcare Shark Tank, now we need the startups. Although someone pointed out on Twitter that Vinod Khosla should be in this group, and it’s true, he should be. So with that addition, what entrepreneurs should be pitching to this group on Friday night?
Deanna, Stephanie, Amanda and I each nominated companies. Here are the criteria:
Montgomery County’s own Sanaria, a emerging biotech company dedicated to the creation of a Malaria vaccine, was named the Verl Zanders Emerging Business of the Year by the Montgomery County Chamber of Commerce.
The award was accepted by CEO Dr. Stephen L. Hoffman during an awards dinner on November 21.
Many medical scientists feel most comfortable at the laboratory bench, developing hypotheses, testing ideas, and running experiments. The US National Institutes of Health (NIH), too, almost exclusively funds this type of hypothesis-driven basic research.
However, bringing a drug, diagnostic tool, or medical device to market requires a lot more than basic research. The problem, scientists say, is that federal funding runs out long before a potential product is ready for investors. “If you've made a discovery with NIH grant money and you want to run some studies in a mouse model, those can be expensive, and it's not the type of study that NIH reviewers typically like. There's this gap in the ability to get money”, says Paul DiCorleto, director of Cleveland Clinic's Lerner Research Institute.
It’s hard to believe that nearly two years after it picked its inaugural class of entrepreneurs to respond to trends in healthcare. Now the health IT accelerator in New York Blueprint Health is gearing up for class number five.
Looking back on its first graduates, Dr. Brad Weinberg, who co-founded the program with Mathew Farkash, noted that seven of the original nine companies are still in business. Five are generating revenue. Looking at its alumni of 39 companies with which it’s invested, 36 of them are still in operation and 80 percent are turning a profit — a record he would challenge other healthcare accelerators to beat.
GSK announced a $1 million dollar prize for innovation in the emerging area of bioelectronics research. This prize will be awarded to the scientists who are first able to solve the challenge of creating a miniaturised, fully implantable device that can read, write and block the body’s electrical signals to treat disease and it is hoped that after finding a solution to this challenge will open and accelerate significant avenues of research in this field.
The scientific challenge was developed and agreed by a group of approximately 150 leading scientists from around the world, brought together by GSK’S Bioelectronics R&D unit at a summit this week in New York. Collectively, summit attendees agreed that if they create an implantable wireless device that can record, stimulate and block neural signals to a single organ, it will be a critical factor enabling the onward development of bioelectronic medicines as a future therapeutic reality.
This year, conversations about creativity and innovation have been happening all over the world. And while there's still a long way to go, we're excited to see just how many schools and communities are embracing the importance of letting a child’s imagination run wild.
A fantastic example of this is when five-year-old Miles Scott became Batkid in San Francisco-turned-Gotham City this November.
AstraZeneca, a global and innovation-driven biopharmaceutical business, has signed an agreement to acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments. AstraZeneca has also agreed to pay various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments up to $225 million when certain assets are subsequently transferred.
Upon completion of the transaction, AstraZeneca will own intellectual property and global rights for the development, manufacture and commercialisation of the diabetes business, which includes Onglyza (saxagliptin), Kombiglyze XR (saxagliptin and metformin HCl extended release), Komboglyze (saxagliptin and metformin HCl), dapagliflozin (marketed as Forxiga outside the US), Byetta (exenatide), Bydureon (exenatide extended-release for injectable suspension), metreleptin and Symlin (pramlintide acetate).
MedImmune, the global biologics research and development arm of AstraZeneca, is pleased to announce its participation in the Brazilian government program, Science Without Borders.
Thirty Brazilian post-doctoral fellows will work at MedImmune’s three sites in Gaithersburg, Maryland, Mountain View, California and Cambridge, UK for a period of two years. The areas of research will include oncology, respiratory, inflammation and autoimmune diseases (RIA), cardiovascular and metabolic diseases (CVMD), infectious diseases, translational science, antibody discovery and protein engineering, and biopharmaceutical development.
When personal genomics and biotech firm 23andMe was founded in Mountain View, Calif., in 2006, the hype over the genetic tests it offered directly to consumers was immediate and irresistible to many. The company promised that for a nominal fee, it could scan your saliva sample and tell you — based on your genetics — everything from who your ancestors were to what diseases you may be at risk of developing many years down the road. 23andMe raised more than $100 million in capital from such big-name investors as Google and Genentech. Today, the company’s website boasts having close to 500,000 “genotyped consumers.”
So it was a surprise to some observers when, on November 22, the U.S. Food & Drug Administration (FDA) sent a strongly worded letter to 23andMe CEO Anne Wojcicki demanding that the company stop marketing its test, called Personal Genome Service (PGS), until it secures authorization from the agency. The FDA contends that PGS is a medical device being pitched for the diagnosis and prevention of disease, and therefore it must obtain approval under federal law.
The three months of intense focus. The crafting of the perfect pitch. The big presentation on demo day, followed by press mentions and meetings with investors.
And…then what? What comes after the accelerator?
For the entrepreneurs of Rock Health’s Boston Class, which wrapped up in August of 2012, there have been four follow-on fundings, some pilot tests, a pivot and a few long quiet periods. I checked in with the entrepreneurs just over a year after they completed to program to see how they’re all doing now.
The National Institutes of Health is releasing funding opportunities to build a new arsenal of tools and technologies for unlocking the mysteries of the brain. The NIH action is in support of President Obama’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative.
The six opportunities announced today were developed in response to high priority areas(PDF – 536KB) identified by the NIH Advisory Committee to the Director’s BRAIN Working Group in September 2013. Awards are expected to be announced in September 2014 and will constitute NIH’s initial investment of $40 million in the initiative.
The Bill & Melinda Gates Foundation just got a physician, big university administrator, and one of the world’s most respected drug developers rolled into one as its new CEO.
Susan Desmond-Hellmann, the chancellor of UC San Francisco since 2009 and the former president of product development at Genentech, has been hired as the new CEO of the Gates Foundation, according to a statement from the foundation. She will start on May 1. UCSF said Sam Hawgood, the dean of the school of medicine, will replace Desmond-Hellmann as interim chancellor.
Combined capabilities provide scientists with access to new and existing immortalized cell lines for use in broad research applications and clinical markets.
ATCC, the premier global biological materials resource and standards organization, and Evercyte GmbH, a proven developer of immortalized human cells, have entered into a strategic partnership to develop and distribute immortalized cell lines that retain key performance characteristics of primary cells. Immortalized primary cell lines enable scientists to have a sufficient supply of physiologically relevant cells for extended studies in biological, medical, pharmaceutical, cosmetic, and toxicological research.
Johns Hopkins University has the sixth-most driven student body in the world, according to data compiled by London-based startup ViewsOnYou.
The website uses three components to match people with a company or employer — energy, interpersonal and intelligence. There are more than 20 metrics that fall into those components, one of which is an individual's drive.
Funding and Research Opportunities
The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:
NIH Guide Notice:
Request for Applications (RFA):
Program Announcement (PA):
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
Startups selected for the DreamIt Health Baltimore accelerator program will get $50,000 in seed funding and access to industry heavyweights like Northrop Grumman Corp.
The defense contractor has signed on as a partner for the new health IT accelerator program, where 10 startups will be selected for the program. The first program runs Jan. 17 through May 9.
People should stop wasting their money on dietary supplements, some physicians said today, in response to three large new studies that showed most multivitamin supplements are ineffective at reducing the risk of disease, and may even cause harm.
The new studies, published today (Dec. 16) in the journal Annals of Internal Medicine —including two new clinical trials and one large review of 27 past clinical trials conducted by the U.S. Preventive Services Task Force — found no evidence that taking daily multivitamin and mineral supplements prevents or slows down the progress of cognitive decline or chronic diseases such as heart diseases or cancer.
On Saturday November 16, participants of the first ever Maryland Leaders on Fast Track (LOFT) symposium gathered at Johns Hopkins University in Rockville to explore STEM careers. The event, hosted by MdBio Foundation and Hispanic Heritage Foundation, drew over 150 participants from Maryland, Virginia, and D.C.
The symposium brought together a diverse student body from local high schools and colleges; over 90 percent of students were minorities and more than half were female. The event also attracted numerous community leaders, including Congressman John Delaney, Congressman Chris Van Hollen, Montgomery County Council President Nancy Navarro, and Montgomery County Executive, Ike Leggett who was awarded the ‘Maryland STEM Education Leader Award’ at the event.
Emergent BioSolutions wants to exercise an option to buy 8 acres next to its East Baltimore manufacturing facility for an expansion that eventually could add up to 100 jobs, a company official said.
The Rockville-based biotechnology company bought its facility on East Lombard Street for $7.85 million in 2009, and has invested $50 million there since, Chief Financial Officer Bob Kramer said.
The City Council is slated to vote Wednesday on the sale of the city-owned parcel next to the facility near Johns Hopkins Bayview Medical Center.
For research universities to produce the ideas and talent the United States needs in order to lead in the 21st century, they “must make a steady and persistent movement to adapt to the times,” according to William (Brit) Kirwan, chancellor of the University System of Maryland (USM).
Kirwan spoke on the future of research universities on Wednesday, Dec. 11, at the University of Delaware. The talk, presented to a group of UD faculty and administrators, was designed to help set the scene and percolate new ideas as UD considers the next phase of its Path to Prominence strategic plan, a process that will begin in the new year.
Instead of looking at pictures in textbooks or working with simulations on computers, high school students across Maryland have a chance to experiment with professional scientists while using the latest lab equipment.
The teens conduct these experiments, not in their classroom, but in a bus outfitted as a mobile laboratory,
The traveling Bio Lab recently visited Patapsco High School and Center for Arts in Baltimore, which delighted of their teacher.
What is your New Year resolution? Get your idea to the market with funding and resources? We can help you!
AccelerateBaltimore™ is an initiative of the Emerging Technology Centers, Baltimore's award winning incubator, and Abell Foundation. In its first two years, we have invested $250,000 in 10 companies. Now, we are looking for the next 6 innovative startup technology companies to add our portfolio.
Apply by December 31, 2013 11:59pm!
Our goal is to close the gap between innovative ideas and getting to market by providing the seed capital, resources, mentors, potential partners and a coworking space. We are looking for 6 exciting startups that use modern technologies to create new business solutions that can be brought to market in 3 months.
There are currently more than 4 million Americans who have been unemployed for 27 weeks or more. This figure doesn’t include those who work part-time or on contracts — or those who, discouraged, have simply stopped trying. Many of them are older and well educated, and their situation doesn’t seem to be improving despite America’s slow crawl out of the recession. While last week’s jobs numbers extolled a decline in the national unemployment rate, the numbers for the long-term unemployed didn’t even budge.
MIT professor Ofer Sharone is tackling this issue head on, piloting a new initiative to help the long-term unemployed and gather valuable research on both job-seeking and hiring practices. He is also the author of the recent book Flawed System/Flawed Self: Job Searching and Unemployment Experiences. My edited discussion with Sharone is below.
I was manning a booth at the Harvard Club of New York’s authors’ night when an older woman approached and picked up a copy of my book, Reinventing You. She paged through it for a moment, then put it down. “Too late for me,” she said abruptly, and walked away.
Over the past six months of my book tour, it’s a question I’ve heard often. Isn’t professional reinvention just for young people? What if I’m too old? How can I spend years training for something new, when I’m already near retirement? It’s true: reinvention is different later in your career. But that doesn’t mean it’s impossible.
GlaxoSmithKline Plc (GSK) (GSK.L) said on Monday it plans to raise its stake in its Indian pharmaceutical unit to up to 75 percent from 50.7 percent through an open offer in a deal worth about 629 million pounds ($1.02 billion).
With the latest India deal, GSK is set to spend close to $2 billion in roughly a year to increase its holdings in two listed Indian companies, underscoring the British drugmaker's drive to deepen its footprint in emerging markets.
The Fort, one of the first startup accelerators in the D.C. area, may be closing its physical doors, but according to Jonathon Perrelli, managing director of Fortify Ventures, it will live on in a blog and in spirit at 1776.
"There's a confusion that The Fort and Fortify Ventures are synonymous," Perrelli explains. They aren't. "We believe in accelerators," he says, "and we want to support early-stage companies." He and the team just don't want to run an accelerator anymore.
The following is an email sent by James P Gavigan, PhD, Head of the Science, Technology and Education Section, Delegation of the European Union to the United States of America regrading the Launch of Horizon 2020.
Dear All,
Please note that the EU's new program to fund research and innovation activities from 2014-2020 - Horizon 2020 – was officially launched on 11 December 2013 with a first tranche of funding of Euros 7.8 billion being made available for calls for proposals in 2014 out of a total of almost 80 billion for the seven year period.
I enclose herewith the Press Release and an accompanying Memo announcing the launch:
http://europa.eu/rapid/press-release_IP-13-1232_en.htm
http://europa.eu/rapid/press-release_MEMO-13-1122_en.htm
I would also like to draw your attention to the new Horizon 2020 web portal which is the unique access point for all information on the program – its content, structure, how to participate, etc.:
http://ec.europa.eu/programmes/horizon2020/
Spring Capital Partners has completed fundraising for a $175 million fund that will invest in small to midsize companies.
The fund is the third — and largest — the Baltimore firm has raised since launching in 1999. Its first in 2000 raised $75 million. The second in 2006 raised $115 million.
Spring’s new fund will buy minority stakes in companies with $10 million to $150 million in revenue. Its investments will not be confined to specific industries, but will span a wide range of companies. Earlier investments have included manufacturers, information technology firms government contractors and software companies.
Being able to learn marketable digital skills is sluggish and difficult — or so they say.
Adda Birnir noticed a gender divide between a media company's business and technical side (read: men) versus the editorial side (read: women). She created online tech education platform Skillcrush to give women a way to learn marketable skills that could lead to steady, high-paying jobs and relevant, satisfying work.
When something like three in four venture-backed startups fail, picking the ones that won’t is definitely not an easy feat.
In search of what they call the “unicorn VCs” of healthcare – investors who have consistently invested in companies with the biggest of the big exits – analysts at research firm CB Insights combed through a decade of healthcare M&A data. They found 50 medical device and biotech companies that exited, through IPO or acquisition, with valuations of at least $500 million between 2004 and 2013.
MedImmune announced on Wednesday a $6.5 million research partnership with Johns Hopkins University, marking the second academic collaboration inked by the Gaithersburg biotech in recent months.
The agreement, which spans five years, will center on projects in oncology, infectious disease, antibody discovery and protein engineering, as well as respiration, inflammation and autoimmunity.
Rockville-based biodefense company Emergent BioSolutions, taking steps to move deeper into the commercial drugmaking world, is paying $222 million to buy Cangene Corp., a Canadian firm, according to the Washington Post.
Emergent emerged as a key biodefense company following the Sept. 11 attacks, when it sold Anthrax vaccines to the U.S. government.